Can-Fite's Compassionate Use Program for Namodenoson
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is making headlines with its recent announcement regarding the compassionate use of its innovative anti-cancer drug, Namodenoson. This pivotal decision comes as the biotechnology company strives to address significant medical needs in the realm of pancreatic cancer treatment.
Understanding Compassionate Use
Compassionate use refers to a process where a physician can request access to an investigational drug for a patient with a serious disease who has no other treatment options available. This program is particularly crucial for patients facing life-threatening conditions like pancreatic cancer, where time is of the essence.
Insight from Leadership
Pnina Fishman, the Chief Scientific Officer and Chairperson at Can-Fite, expressed her enthusiasm about offering Namodenoson through this compassionate use program. She acknowledged the urgent medical requirements of pancreatic cancer patients and reaffirmed the company’s commitment to advancing therapeutic options in this rigorous fight against cancer.
The Role of Namodenoson in Cancer Treatment
Namodenoson is an orally bioavailable drug that specifically targets the A3 adenosine receptor (A3AR), which plays a significant role in cancer treatment due to its differential expression in diseased versus normal cells. Currently, Namodenoson is undergoing extensive evaluation through various clinical trials, including a pivotal Phase III trial for advanced liver cancer, which has already gained approvals from both the FDA and the European Medicines Agency (EMA).
Furthermore, it is also being tested in a Phase II clinical trial focused on pancreatic cancer, signifying its versatility and potential as a treatment option across different types of cancer.
Regulatory Designation and Market Potential
The FDA has granted Namodenoson Orphan Drug Designation for pancreatic cancer, which provides certain advantages such as a 7-year market exclusivity post-approval. This designation strengthens the company’s position in the market and reflects the drug’s promising prospects for treating this critical condition.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. operates at the forefront of drug development, targeting substantial markets in oncology, liver disease, and inflammatory disorders. The company’s primary drug candidate, Piclidenoson, recently announced significant results from a Phase III psoriasis trial, demonstrating Can-Fite's dedication to rigorous clinical advancement.
Namodenoson is not only a focus for pancreatic cancer but also shows potential in treating liver diseases, metabolic disorders, and possibly various cancers, including those of the colon and prostate. Furthermore, the company is also advancing CF602, its candidate for treating erectile dysfunction, adding to its diverse pipeline.
Contact Information
For those interested in learning more about Can-Fite's programs and research, Motti Farbstein is the contact person at the company. You can reach out via email at info@canfite.com or by phone at +972-3-9241114.
Frequently Asked Questions
What is the purpose of the compassionate use program?
The compassionate use program allows patients with serious conditions, like pancreatic cancer, to access investigational drugs that are not yet approved by the FDA.
What is Namodenoson?
Namodenoson is a small molecule drug that targets the A3 adenosine receptor, showing promise in treating various cancers and liver diseases.
What clinical trials is Namodenoson involved in?
Currently, Namodenoson is being evaluated in several clinical trials, including Phase III for liver cancer and Phase II for pancreatic cancer.
What regulatory advantages does Namodenoson have?
Namodenoson has received Orphan Drug Designation from the FDA, providing potential market exclusivity and certain regulatory benefits.
Who can I contact for more information?
For inquiries, you can contact Motti Farbstein at Can-Fite BioPharma via email at info@canfite.com or call +972-3-9241114.
